Zymeworks Inc (ZYME)

$8.43

-0.05

(-0.59%)▲

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Zymeworks Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 16.92M → 10.03M (in $), with an average decrease of 40.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -14.48M → -31.65M (in $), with an average decrease of 118.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 75.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 308.5%

Performance

  • $8.43
    $9.31
    $8.43
    downward going graph

    0.0%

    Downside

    Day's Volatility :9.4%

    Upside

    9.4%

    downward going graph
  • $6.02
    $13.14
    $8.43
    downward going graph

    28.59%

    Downside

    52 Weeks Volatility :54.19%

    Upside

    35.84%

    downward going graph

Returns

PeriodZymeworks IncRussel 2000Index (Russel 2000)
3 Months
-32.61%
0.0%
0.0%
6 Months
-8.67%
0.0%
0.0%
1 Year
-5.7%
0.0%
0.0%
3 Years
-73.42%
-22.6%
-22.6%

Highlights

Market Capitalization
641.3M
Book Value
$6.2
Earnings Per Share (EPS)
-1.78
PEG Ratio
0.0
Wall Street Target Price
14.36
Profit Margin
-249.63%
Operating Margin TTM
-383.87%
Return On Assets TTM
-16.15%
Return On Equity TTM
-27.64%
Revenue TTM
50.5M
Revenue Per Share TTM
0.71
Quarterly Revenue Growth YOY
-71.8%
Gross Profit TTM
203.8M
EBITDA
-142.2M
Diluted Eps TTM
-1.78
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.06
EPS Estimate Next Year
-1.14
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.08

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Zymeworks Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 70.34%

Current $8.43
Target $14.36

Company Financials

FY18Y/Y Change
Revenue
53.0M
↑ 2.43%
Net Income
-36.6M
↑ 251.3%
Net Profit Margin
-68.95%
↓ 48.85%
FY19Y/Y Change
Revenue
29.5M
↓ 44.28%
Net Income
-145.4M
↑ 297.85%
Net Profit Margin
-492.27%
↓ 423.32%
FY20Y/Y Change
Revenue
39.0M
↑ 31.84%
Net Income
-180.6M
↑ 24.14%
Net Profit Margin
-463.54%
↑ 28.73%
FY21Y/Y Change
Revenue
26.7M
↓ 31.5%
Net Income
-211.8M
↑ 17.33%
Net Profit Margin
-794.01%
↓ 330.47%
FY22Y/Y Change
Revenue
412.5M
↑ 1446.03%
Net Income
124.3M
↓ 158.69%
Net Profit Margin
30.14%
↑ 824.15%
FY23Y/Y Change
Revenue
76.0M
↓ 81.57%
Net Income
-118.7M
↓ 195.44%
Net Profit Margin
-156.13%
↓ 186.27%
Q4 FY22Q/Q Change
Revenue
402.5M
↑ 15198.1%
Net Income
309.4M
↓ 746.72%
Net Profit Margin
76.88%
↑ 1895.43%
Q1 FY23Q/Q Change
Revenue
35.6M
↓ 91.16%
Net Income
-24.4M
↓ 107.87%
Net Profit Margin
-68.45%
↓ 145.33%
Q2 FY23Q/Q Change
Revenue
7.0M
↓ 80.32%
Net Income
-51.2M
↑ 110.04%
Net Profit Margin
-730.53%
↓ 662.08%
Q3 FY23Q/Q Change
Revenue
16.5M
↑ 135.73%
Net Income
-28.7M
↓ 43.92%
Net Profit Margin
-173.8%
↑ 556.73%
Q4 FY23Q/Q Change
Revenue
16.9M
↑ 2.54%
Net Income
-14.5M
↓ 49.52%
Net Profit Margin
-85.56%
↑ 88.24%
Q1 FY24Q/Q Change
Revenue
10.0M
↓ 40.74%
Net Income
-31.7M
↑ 118.57%
Net Profit Margin
-315.58%
↓ 230.02%
FY18Y/Y Change
Total Assets
244.4M
↑ 85.19%
Total Liabilities
63.9M
↑ 311.37%
FY19Y/Y Change
Total Assets
368.2M
↑ 50.68%
Total Liabilities
122.5M
↑ 91.82%
FY20Y/Y Change
Total Assets
538.4M
↑ 46.22%
Total Liabilities
128.5M
↑ 4.84%
FY21Y/Y Change
Total Assets
389.1M
↓ 27.72%
Total Liabilities
140.0M
↑ 9.02%
FY22Y/Y Change
Total Assets
648.7M
↑ 66.71%
Total Liabilities
155.8M
↑ 11.23%
FY23Y/Y Change
Total Assets
580.9M
↓ 10.46%
Total Liabilities
116.1M
↓ 25.48%
Q4 FY22Q/Q Change
Total Assets
648.7M
↑ 116.05%
Total Liabilities
155.8M
↑ 29.26%
Q1 FY23Q/Q Change
Total Assets
600.7M
↓ 7.4%
Total Liabilities
127.2M
↓ 18.34%
Q2 FY23Q/Q Change
Total Assets
602.1M
↑ 0.22%
Total Liabilities
153.1M
↑ 20.38%
Q3 FY23Q/Q Change
Total Assets
556.4M
↓ 7.59%
Total Liabilities
132.0M
↓ 13.79%
Q4 FY23Q/Q Change
Total Assets
580.9M
↑ 4.41%
Total Liabilities
116.1M
↓ 12.08%
Q1 FY24Q/Q Change
Total Assets
553.8M
↓ 4.67%
Total Liabilities
115.8M
↓ 0.28%
FY18Y/Y Change
Operating Cash Flow
24.2M
↑ 10939.73%
Investing Cash Flow
-109.0M
↑ 253.04%
Financing Cash Flow
91.4M
↑ 83.04%
FY19Y/Y Change
Operating Cash Flow
-81.9M
↓ 438.56%
Investing Cash Flow
-25.6M
↓ 76.53%
Financing Cash Flow
193.7M
↑ 111.81%
FY20Y/Y Change
Operating Cash Flow
-151.4M
↑ 84.97%
Investing Cash Flow
-43.4M
↑ 69.74%
Financing Cash Flow
309.0M
↑ 59.55%
FY21Y/Y Change
Operating Cash Flow
-192.5M
↑ 27.11%
Investing Cash Flow
144.6M
↓ 432.86%
Financing Cash Flow
8.0M
↓ 97.41%
FY22Y/Y Change
Operating Cash Flow
144.1M
↓ 174.88%
Investing Cash Flow
-53.8M
↓ 137.24%
Financing Cash Flow
108.6M
↑ 1255.41%
Q4 FY22Q/Q Change
Operating Cash Flow
327.4M
↓ 548.35%
Investing Cash Flow
-22.1M
↓ 27.48%
Financing Cash Flow
-377.0K
↓ 160.03%
Q1 FY23Q/Q Change
Operating Cash Flow
-83.2M
↓ 125.41%
Investing Cash Flow
-138.2M
↑ 526.43%
Financing Cash Flow
1.7M
↓ 561.01%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.4M
↓ 92.31%
Investing Cash Flow
-60.7M
↓ 56.1%
Financing Cash Flow
27.6M
↑ 1488.15%
Q3 FY23Q/Q Change
Operating Cash Flow
-42.7M
↑ 566.78%
Investing Cash Flow
-7.0M
↓ 88.43%
Financing Cash Flow
1.9M
↓ 93.13%

Technicals Summary

Sell

Neutral

Buy

Zymeworks Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zymeworks Inc
Zymeworks Inc
-6.95%
-8.67%
-5.7%
-73.42%
-73.69%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zymeworks Inc
Zymeworks Inc
3.56
NA
0.0
-1.06
-0.28
-0.16
NA
6.2
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zymeworks Inc
Zymeworks Inc
Buy
$641.3M
-73.69%
3.56
-249.63%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • EcoR1 Capital, LLC

    19.01%

  • Bvf Inc

    8.30%

  • Redmile Group, LLC

    7.86%

  • Morgan Stanley - Brokerage Accounts

    7.23%

  • BlackRock Inc

    5.79%

  • Rubric Capital Management LP

    4.92%

Company Information

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.

Organization
Zymeworks Inc
Employees
275
CEO
Mr. Kenneth H. Galbraith C.A.
Industry
Health Technology

Discover More

FAQs